http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-070735-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28e3113097dd6d28720572e47f2f2407 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| filingDate | 2009-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70e0a33aa2a1520c0523c8b2ea5a78cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38a652d808f21e2dff4d249d37c415d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dec1149f983cb505373f0b802d7e4a92 |
| publicationDate | 2010-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-070735-A1 |
| titleOfInvention | PHARMACO COMBINED FOR THE TREATMENT OF CANCER. |
| abstract | A pharmaceutical agent containing an HER2 inhibitor and a hormonal therapeutic agent or anti-cancer agent in combination is provided. That is, a pharmaceutical agent containing (a) a compound represented by the formula (1) wherein R 1 is a hydrogen atom; R2 is a C1-6 alkyl group substituted with a group represented by -NR6-CO- (CH2) n-SO2- (optionally halogenated C1-4 alkyl) (n is an integer from 1 to 4, R6 is an atom of hydrogen or a C1-4 alkyl group and - (CH2) n- is optionally substituted with C1-4 alkyl); R3 is a hydrogen atom or a C1-6 alkyl group; R4 is a halogen atom or a C1-6 alkyl group; R5 is a halogen atom or a C1-6 alkyl group; and X is a hydrogen atom or a halogen atom; except N- [2- (4 - {[3-chloro-4- (3-chlorophenoxy) phenyl] amino} -5H-pyrrolo [3,2-d] pyrimidin-5-yl) ethyl] -2- (methylsulfonyl ) acetamide or one of its salts or one of its prodrugs; and (b) a hormonal therapeutic agent or anticancer agent in combination. Claim 11: The pharmaceutical agent according to claim 1, wherein the anti-cancer agent is an HER2 antibody, an EGFR antibody, an EGFR inhibitor, a VEGFR inhibitor or a chemotherapeutic agent. Claim 12: The pharmaceutical agent according to claim 1, wherein the anticancer agent is trastuzumab, cetuximab, erlotinib, gefitinib or paclitaxel. Claim 13: The pharmaceutical agent according to claim 1, wherein the hormonal therapeutic agent is a down ER regulator. Claim 14: The pharmaceutical agent according to claim 1, wherein the hormonal therapeutic agent is fulvestrant. |
| priorityDate | 2008-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.